Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis by Bernatsky, S et al.
Short Communication
Breast, ovarian, and endometrial malignancies in systemic lupus
erythematosus: a meta-analysis
S Bernatsky*,1,2, R Ramsey-Goldman
3, WD Foulkes
4, C Gordon
5 and AE Clarke
2,6
1Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada;
2Division of Clinical Epidemiology, Research Institute of the McGill
University Health Centre, 687 Pine Avenue West, V-Building, V2.09, Montreal, QC H3A 1A1, Canada;
3Division of Rheumatology, Northwestern
University, Chicago, IL, USA;
4Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, QC, Canada;
5Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Birmingham, UK;
6Division of Clinical Immunology/
Allergy, McGill University Health Centre, Montreal, QC, Canada
BACKGROUND: An increased lymphoma risk is well documented in systemic lupus (SLE). Less attention has been focused on women’s
cancers, even though SLE affects mostly females. Our objective was to estimate the risk of breast, ovarian, and endometrial cancers
in SLE, relative to the general population.
METHODS: Data were included from five recent studies of large SLE cohorts. The number of cancers observed was determined for
each cancer type. The expected number of malignancies was ascertained from general population data. The parameter of interest
was the standardised incidence ratio (SIR), the ratio of observed to expected malignancies.
RESULTS: The five studies included 47325 SLE patients (42171 females) observed for 282553 patient years. There were 376 breast
cancers, 66 endometrial cancers, and 44 ovarian cancers. The total number of cancers observed was less than that expected, with
SIRs of 0.76 (95% CI: 0.69, 0.85) for breast cancer, 0.71 (95% CI: 0.55, 0.91) for endometrial cancer, and 0.66 (95% CI: 0.49, 0.90) for
ovarian cancer.
CONCLUSIONS: Data strongly support a decreased risk of breast, ovarian, and endometrial cancers in SLE. This may be due to inherent
differences in women in SLE (vs the general population) regarding endogenous oestrogen, other medications, and/or genetic
make-up.
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An increased risk of lymphoma in systemic lupus erythematosus
(SLE) has been the focus of much attention, particularly in the
last decade (Gayed et al, 2009). However, as SLE is a disease
predominantly of women, some of the most prevalent types of
malignancies in SLE are actually those that commonly occur
in women in the general population – breast, ovarian, and
endometrial cancers. Despite this, much less attention has been
focussed on these malignancies. Our objective was to estimate the
risk of breast, ovarian, and endometrial cancers in women with
SLE, relative to an age, calendar year, and geographically matched
general population.
METHODS
A literature review was conducted to identify published peer-
reviewed articles documenting cancer occurrence in SLE, with a
focus on observational cohort designs. It has been established
(Furlan et al, 2006) that standard systematic literature searches
do not effectively identify key manuscripts when observational
designs are of primary interest. Thus, as per Furlan et al (2006),
we completed a progressive literature search. This methodology
involves identifying key articles from existing reviews of the
literature, and then using search terms (in Medline, MeSH terms)
from these citations to locate additional articles. Progressive search
strategies locate essentially 100% of articles as compared with
traditional systematic literature searches (Furlan et al, 2006).
For our analyses, we reviewed all cohort studies published since
1995, which provided basic descriptive information (regarding
cohort assembly, demographics, person-time of observation, etc.),
and cancer outcomes. The date of 1995 was chosen because the
vast majority of the literature regarding cancer risk in SLE
(including those with most rigorous methods) has been published
in the last 10–15 years. However, several studies of cancer in SLE
published since 1995 have come from centres that later contributed
data to the international multi-centre cohort study of cancer in
SLE, published in 2005 (Bernatsky et al, 2005b). Such studies were
themselves excluded from our current analyses, as they were
essential subset analyses of the larger multi-centre sample. To
ensure the quality of the data included, we additionally required
that outcome ascertainment was made through cancer registry
linkage. The criteria for inclusion in our current analyses were thus
as follows: studies of cancer occurrence in SLE cohorts published
since 1995, where cancer registry linkage had been conducted to
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yascertain cancer occurrence, provided they were not replicated in
other larger published data sets.
In our primary analysis, we did not consider random effects; the
total number of cancers observed across all studies was summed
for each of the three different cancer types (breast, endometrial,
and ovarian). The total expected number of malignancies for
each cancer type, derived in each study from applying general
population cancer incidence data to the observed number of
patient years of follow-up for each study, was similarly deter-
mined. Patients who contributed a cancer of one type could still
contribute person-time and events for other cancer types. Our
parameter of interest was the standardised incidence ratio (SIR),
the ratio of observed to expected malignancies. The 95%
confidence interval (CI) for each SIR was estimated by considering
the observed number of cancers as a Poisson-distributed variable
and finding its related interval from published tables (Breslow and
Day, 1987).
The studies examined all patients in the cohort and did not
exclude patients with a previous history of cancer. Of course
cancer events that had occurred before SLE diagnosis (and cohort
entry) were not included, but the patients with a history of
previous cancer were still followed and contributed patient-time
just like the others, and if they developed a cancer during the
follow-up that event was included.
As SIRs for cancer may differ across centres, we also fit a
random-effects hierarchical model allowing differences among
studies, rather than assuming a single fixed rate across all.
Standardised incidence ratio estimation using this hierarchical
modelling represents a compromise between the summing of data
across sites (our primary analysis, which assumes no variation in
cancer experience from one centre to the next) vs independent
estimates for each centre (the other extreme, which would preclude
estimation of a single SIR). We used the Gibbs sampler as
implemented with WinBUGS 1.4 software to estimate the model
parameters, with 95% credible intervals (CrI) (Gelman et al, 1995).
RESULTS
Of the cohort studies of cancer occurrence in SLE that have been
published since 1995, six provided data for the international
cohort study published in 2005 (Bernatsky et al, 2005b). These
smaller subset analyses (Sweeney et al, 1995; Abu-Shakra et al,
1996; Ramsey-Goldman et al, 1998; Sultan et al, 2000; Cibere et al,
2001; Nived et al, 2001) were excluded, whereas the larger
international cohort study was included, along with four other
large cohort studies from Sweden (Bjornadal et al, 2002), Denmark
(Mellemkjaer et al, 1997), the United States (Parikh-Patel et al,
2008), and South Korea (Kang et al, 2010).
The five studies identified (Table 1) together included 47325
SLE patients (42171 of these female) observed for a total of 282553
patient years (mean 5.9 years). The overall cancer SIR for each
study was in keeping with a slight increase in total cancer risk
(which in each study had been demonstrated to be largely driven
by an increased risk of haematological malignancy). In total, there
were 376 breast cancers, 66 endometrial cancers, and 44 ovarian
cancers. In each case, the total number of cancers expected far
exceeded that observed, with SIRs of 0.76 (95% CI: 0.69, 0.85) for
breast cancer, 0.71 (95% CI: 0.55, 0.91) for endometrial cancer, and
0.66 (95% CI: 0.49, 0.90) for ovarian cancer. Our random-effects
model produced very similar findings, with an SIR of 0.76 (95% CrI:
0.68, 0.84) for breast cancer, 0.72 (95% CrI: 0.56, 0.91) for endometrial
cancer, and 0.69 (95% CrI: 0.50, 0.90) for ovarian cancer.
DISCUSSION
In western countries, breast cancer has the highest incidence rate
of all non-skin cancers (Curado et al, 2007). Endometrial cancer is
the most common cancer of the female reproductive system and is
one of the top five highest-incident cancers among women in the
developed world (Curado et al, 2007). Like breast cancer, the risk
of endometrial cancer increases with oestrogen exposure, both
endogenously and via hormone replacement therapy (Pike et al,
1997). In addition, ovarian cancers may be precipitated by
oestrogen exposure (Xu et al, 2004; Beral et al, 2007). In the
general population, late menopause can increase both breast and
endometrial cancer risk (La Vecchia et al, 1984; Peeters et al,
1994). Women with SLE have been shown to have earlier
menopause (even when not exposed to cytotoxic medications),
as compared with women without SLE (Cooper et al, 2002). This
reproductive factor could be one of the driving forces behind the
observed decreased risk of breast, endometrial, and possibly ovarian
cancers in SLE. We are currently exploring this in a very large multi-
centre study of cancer incidence in SLE (Bernatsky et al, 2010).
However, because our preliminary data suggest that breast cancer in
SLE is decreased in both pre-menopausal and post-menopausal
women, we suspect that there are additional factors contributing to
a protective effect for certain cancers in SLE.
Other medication exposures are of interest. Hydroxychloroquine
is an anti-malarial drug often used in SLE, and this has theoretically
some potential to inhibit the growth of breast cancer cells (Rahim
and Strobl, 2009). However, one earlier report of a potential
beneficial effect of antimalarial agents against malignancy in
rheumatic diseases like SLE (Ruiz-Irastorza et al, 2007) has not
necessarily been supported by other studies (King and Costenbader,
2007; Bernatsky et al, 2008a). Intriguingly, although concerns have
long existed regarding the carcinogenic potential of immunosup-
pressive drugs, results from a recent case–cohort study did not
establish these agents as independently associated with cancer risk
for non-haematological malignancies in SLE (Bernatsky et al,
2008b). In fact, there was a trend, although non-significant, towards
fewer non-haematological malignancies treated with immunosup-
pressive agents (the adjusted hazard ratio for overall cancer risk
after any immunosuppressive drug was 0.82, 95% CI 0.50–1.36).
Again, we are completing additional case–cohort analyses in the
context of our expanded multi-centre international cohort study
(Ruiz-Irastorza et al, 2007), which may be able to identify more
precisely the role of these agents (relative to the risk related to the
disease itself) in cancer risk for women with SLE.
Table 1 Characteristics of the five recent large cohort studies of cancer in systemic lupus erythematosus
Study Population N total Mean person-years follow-up N females Over-all SIR (95% CI) NHL SIR (95% CI)
Bernatsky et al (2005a,b) Multi centre clinical 9547 6.0 8607 1.15 (1.05–1.27) 3.64 (2.63–4.93)
Bjornadal et al (2002) Sweden administrative 5715 8.8 4201 1.25 (1.14–1.37) 2.86 (1.96–4.04)
Kang et al (2010) South Korea clinical 914 6.3 914 1.45 (0.74–2.16) 15.4 (2.90–37.7)
Mellemkjaer et al (1997) Danish administrative 1585 6.8 1316 1.30 (1.06–1.58) 5.2 (2.2–10.3)
Parikh-Patel et al (2008) USA administrative 30478 5.2 27133 1.14 (1.07–1.20) 2.74 (2.22–3.34)
Total 47325 5.9 42171
Abbreviations: SIR¼standardised incidence ratio; CI¼confidence interval.
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yGenetic factors might also underpin this association breast and
ovarian cancers are components of several autosomal dominant
cancer syndromes. The syndromes most strongly associated
with both cancers are the BRCA1 or BRCA2 mutation syndromes
(Narod et al, 1995), but these do not account for most breast
cancers that arise in the general population. Genome-wide asso-
ciation studies have identified common variants (single nucleotide
polymorphisms, (SNPs)) at various loci that are associated with an
increased risk of breast cancer (Easton et al, 2007). Various genetic
variants within 8q24 have been linked to breast, prostate, and
other cancers (Ghoussaini et al, 2008). We are pursuing studies of
data from genome-wide association studies in unselected SLE
patients, to help to determine whether some of these specific
cancer-related SNPs have a lower frequency than expected in
persons with SLE.
Regarding overall cancer risk, the data present do not include
wash-out periods, but in our large multi-centre cohort we did in
sensitivity analyses exclude the first year of SLE diagnosis to
account for the potential of paraneoplastic syndromes. This did
not change the results. We note that the study cohorts of
Mellemkjer, Bjornadal, and Patel et al represented SLE patients
drawn from hospitalisation records (where the SLE diagnosis was
not necessarily clinically confirmed), whereas the study cohorts of
Bernatsky and by Kang were drawn from clinical registries (and all
subjects had clinically confirmed SLE. However, the follow-up time
was not systematically different, and the SIR results were
remarkably similar. One discernable difference in terms of
demographics between the hospital-based cohorts and the clinical
cohorts was that there was a tendency for a slightly greater
proportion of males with the hospital-based cohort, but again this
did not seem to influence the results.
Considering Table 2, the results are relatively homogeneous, but
in some cases the data from Kang et al are a bit discrepant. In most
cohorts the patients were primarily Caucasian, whereas the study
of Kang et al featured Asian patients. This suggests that perhaps
the cancer profile of SLE patients may be influenced by race. A
potential limitation is that we did not have information about
cancer risk stratified by race. However, race-specific SIRs for
cancers overall have been published using data from the
international multi-centre SLE cohort (Bernatsky et al, 2005a).
Those analyses demonstrated similar SIRs for cancer risk overall in
black and white patients with SLE, although precise estimates for
Asians could not be demonstrated. As the multi-centre study is
being updated, with twice as many patient years as previously,
future data may help to resolve the issue (Bernatsky et al, 2010).
In summary, the published data to date strongly support a
decreased risk of breast, ovarian, and endometrial malignancies in
women with SLE. This may be due to inherent differences in
women in SLE (vs the general population) with respect to
endogenous oestrogen or other medications, and/or genetic
make-up. Further studies may elucidate this.
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